Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

Mannion M, Raeppel S, Claridge S, Zhou N, Saavedra O, Isakovic L, Zhan L, Gaudette F, Raeppel F, Déziel R, Beaulieu N, Nguyen H, Chute I, Beaulieu C, Dupont I, Robert MF, Lefebvre S, Dubay M, Rahil J, Wang J, Ste-Croix H, Robert Macleod A, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6552-6. doi: 10.1016/j.bmcl.2009.10.040. Epub 2009 Oct 13.

PMID:
19854051
2.

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

Raeppel S, Claridge S, Saavedra O, Gaudette F, Zhan L, Mannion M, Zhou N, Raeppel F, Granger MC, Isakovic L, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Robert MF, Lefebvre S, Dubay M, Rahil J, Wang J, Ste-Croix H, Robert Macleod A, Besterman J, Vaisburg A.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1323-8. doi: 10.1016/j.bmcl.2009.01.068. Epub 2009 Jan 27.

PMID:
19211249
3.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Harmange JC, Weiss MM, Germain J, Polverino AJ, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, DiPietro L, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Martin MW, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Wang L, White RD, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7.

PMID:
18324761
4.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Claridge S, Raeppel F, Granger MC, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R, Rahil J, Beaulieu N, Nguyen H, Dupont I, Barsalou A, Beaulieu C, Chute I, Gravel S, Robert MF, Lefebvre S, Dubay M, Pascal R, Gillespie J, Jin Z, Wang J, Besterman JM, MacLeod AR, Vaisburg A.

Bioorg Med Chem Lett. 2008 May 1;18(9):2793-8. doi: 10.1016/j.bmcl.2008.04.009. Epub 2008 Apr 9.

PMID:
18434145
5.

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.

Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA.

J Med Chem. 2008 Nov 27;51(22):7049-52. doi: 10.1021/jm801050k.

PMID:
18942827
6.

Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.

Trova MP, Barnes KD, Barford C, Benanti T, Bielaska M, Burry L, Lehman JM, Murphy C, O'Grady H, Peace D, Salamone S, Smith J, Snider P, Toporowski J, Tregay S, Wilson A, Wyle M, Zheng X, Friedrich TD.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6608-12. doi: 10.1016/j.bmcl.2009.10.025. Epub 2009 Oct 12.

PMID:
19846305
7.

N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Saavedra O, Claridge S, Zhan L, Raeppel F, Granger MC, Raeppel S, Mannion M, Gaudette F, Zhou N, Isakovic L, Bernstein N, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Wang J, Macleod AR, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6836-9. doi: 10.1016/j.bmcl.2009.10.095. Epub 2009 Oct 25.

PMID:
19896842
8.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1668-80. doi: 10.1021/jm701098w. Epub 2008 Mar 7.

PMID:
18324759
9.

Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

Xu G, Searle LL, Hughes TV, Beck AK, Connolly PJ, Abad MC, Neeper MP, Struble GT, Springer BA, Emanuel SL, Gruninger RH, Pandey N, Adams M, Moreno-Mazza S, Fuentes-Pesquera AR, Middleton SA, Greenberger LM.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3495-9. doi: 10.1016/j.bmcl.2008.05.024. Epub 2008 May 10.

PMID:
18508264
10.

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.

J Med Chem. 2002 Mar 14;45(6):1300-12.

PMID:
11881999
11.

Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.

Trova MP, Barnes KD, Alicea L, Benanti T, Bielaska M, Bilotta J, Bliss B, Duong TN, Haydar S, Herr RJ, Hui Y, Johnson M, Lehman JM, Peace D, Rainka M, Snider P, Salamone S, Tregay S, Zheng X, Friedrich TD.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6613-7. doi: 10.1016/j.bmcl.2009.10.011. Epub 2009 Oct 12.

PMID:
19854650
12.

Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.

Gracias V, Ji Z, Akritopoulou-Zanze I, Abad-Zapatero C, Huth JR, Song D, Hajduk PJ, Johnson EF, Glaser KB, Marcotte PA, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR, Djuric SW.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2691-5. doi: 10.1016/j.bmcl.2008.03.021. Epub 2008 Mar 10.

PMID:
18362070
13.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Zhang D, Ai J, Liang Z, Li C, Peng X, Ji Y, Jiang H, Geng M, Luo C, Liu H.

Bioorg Med Chem. 2012 Sep 1;20(17):5169-80. doi: 10.1016/j.bmc.2012.07.007. Epub 2012 Jul 16.

PMID:
22863529
14.

Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.

Ye Q, Cao J, Zhou X, Lv D, He Q, Yang B, Hu Y.

Bioorg Med Chem. 2009 Jul 1;17(13):4763-72. doi: 10.1016/j.bmc.2009.04.043. Epub 2009 May 3.

PMID:
19447039
15.
16.

From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.

Dussault I, Bellon SF.

Anticancer Agents Med Chem. 2009 Feb;9(2):221-9. Review.

PMID:
19199866
17.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.

J Med Chem. 1998 Aug 13;41(17):3276-92.

PMID:
9703473
18.

Design, synthesis, and preclinical evaluation of new 5,6- (or 6,7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agents.

Chou LC, Tsai MT, Hsu MH, Wang SH, Way TD, Huang CH, Lin HY, Qian K, Dong Y, Lee KH, Huang LJ, Kuo SC.

J Med Chem. 2010 Nov 25;53(22):8047-58. doi: 10.1021/jm100780c. Epub 2010 Oct 25.

PMID:
20973552
19.

Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.

Ban HS, Tanaka Y, Nabeyama W, Hatori M, Nakamura H.

Bioorg Med Chem. 2010 Jan 15;18(2):870-9. doi: 10.1016/j.bmc.2009.11.035. Epub 2009 Nov 22.

PMID:
19969465
20.

Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT.

Bioorg Med Chem. 2011 Jul 15;19(14):4173-82. doi: 10.1016/j.bmc.2011.06.016. Epub 2011 Jun 13.

PMID:
21708468
Items per page

Supplemental Content

Write to the Help Desk